One patient received its Duchenne gene therapy Elevidys this week and a handful more could follow shortly, surprising some analysts and raising near-term sales expectations.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,